Terbinafine vs. placebo for onychomycosis in black patients

International Journal of Dermatology

Volumn 38, Issue 5, 1999, Pages 377-379

  Billstein, Stephan ^a   Kianifard, Fand ^a   Justice, Angela ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; POTASSIUM HYDROXIDE; TERBINAFINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FUNGUS CULTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEGRO; ONYCHOMYCOSIS; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; TOE; TRICHOPHYTON RUBRUM; UNITED STATES;

ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; ANTIFUNGAL AGENTS; DOUBLE-BLIND METHOD; FEMALE; FOOT DERMATOSES; HUMANS; MALE; MIDDLE AGED; NAPHTHALENES; ONYCHOMYCOSIS; PLACEBOS; TIME FACTORS; TREATMENT OUTCOME; TRICHOPHYTON;

EID: 0033034872     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-4362.1999.00713.x     Document Type: Article

References (9)

1. Scher RK. Onychomycosis is more than a cosmetic problem. Br J Dermatol 1994; 130 (Suppl. 43): 15.
2. Elewski BE. Large-scale epidemiological study of the causal agents of onychomycosis: mycological findings from the multicenter onychomycosis study of terbinafine. Arch Dermatol 1997; 133: 1317-1318.
3. Ryder NS. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol 1992; 126 (Suppl. 39): 2-7.
4. Petranyi G, Meingassner JG, Mieth H. Antifungal activity of the allylamine derivative terbinafine in vitro. Antimicrob Agents Chemother 1987; 31: 1365-1368.
5. Clayton YM. In vitro activity of terbinafine. Clin Exp Dermatol 1989; 14: 101-103.
6. Clayton YM. Relevance of broad-spectrum and fungicidal activity of antifungals in the treatment of dermatomycoses. Br J Dermatol 1994; 130 (Suppl. 43): 7-8.
7. Bräutigam M, Nolting S, Schopf RE, Weidinger G, for the Seventh Lamisil German Onychomycosis Group. Br Med J 1995; 311: 919-922.
8. De Backer M, De Keyser P, De Vroey C, Lesaffre E. A 12-week treatment for dermatophyte toe onychomycosis: terbinafine 250 mg/day vs. itraconazole 200 mg/day - a double-blind comparative trial. Br J Dermatol 1996; 134 (Suppl. 46): 16-17.
9. Drake LA, Shear NH, Arlette JP, et al. Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. J Am Acad Dermatol 1997; 37: 740-745.